3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Deanna Zhang of Tudor, Pickering, & Holt Co., Sarma Velamuri of Luminare, and Amy Chronis of Deloitte. Courtesy photos

Editor's note: In the week's roundup of Houston innovators to know, I'm introducing you to three innovators recently making headlines — from health tech founders to the new GHP chair.

Deeana Zhang, director of energy technology at Tudor, Pickering, Holt & Co.

Deanna Zhang of Tudor, Pickering, Holt & Co. joined the Houston Innovators Podcast to discuss 2020's effect on the energy transition — and what that meant for startups. Photo courtesy of TPH

Deanna Zhang looks closely at the energy innovation market and, well, last year was extremely enlightening about the energy industry and where tech is taking it. She joined the Houston Innovators Podcast last week to discuss some of the 2020 trends and observations she had — and what that means for 2021.

"The energy transition saw a huge uptick in 2020 — and there's a lot of implications of that from what pilots are getting commercialized and what companies are getting more funding," says Zhang. "All around it was hugely disruptive — but hugely beneficial I think to the energy transition." Click here to read more and stream the episode.

Dr. Sarma Velamuri, CEO of Luminare

A Houston health tech startup has launched a COVID-19 vaccine management tool. Image via luminaremed.com

As great as it was to be able to begin distributing the life-saving COVID-19 vaccine, the logistics of the two-dose process was a nightmare. Dr. Sarma Velamuri, CEO of Luminare, thought he could innovate a solution. His new platform, Innoculate (a mash-up of "innovate" and "inoculate"), enables organizations like public health departments, fire departments, school systems, and businesses to manage high-volume vaccination initiatives.

"Usually when you hear news of a new batch of vaccines headed your way, there is dread at the management and distribution overhead. Not anymore," Velamuri says in a release. "Innoculate will help streamline the vaccination process in the fight against COVID-19 and allow for hundreds of thousands of people to get vaccines easily." Click here to read more.

Amy Chronis, Greater Houston Partnership's 2021 chair and the Houston managing partner at Deloitte

Houston, we have a perception problem — but the Greater Houston Partnership's new chair, Amy Chronis, is here to fix it. Photo courtesy Deloitte/AlexandersPortraits.com

Hey Houston, it's time to speak up — a little louder for the people in the back. That's what Amy Chonis, 2021 chair for the Greater Houston Partnership, wants you to know, and that it's important for business leaders across the city to take the initiative about how great Houston is.

"We just don't brag enough about how much the city has changed and its trajectory," she tells InnovationMap.

While Houston has long been innovative in the health, space, and energy industries, it has a perception problem. Recently, Chronis addressed some of these concerns in her address at the GHP's 2021 Annual Meeting. She joined InnovationMap for an interview to zero in on how the business community can work to change this perception problem and continue to grow its innovation and tech community. Click here to read the Q&A.

Image via luminaremed.com

Houston health tech startup launches COVID-19 vaccine management tool

inoculation innovation

Houston-based health care software startup Luminare Inc. is arming soldiers in the coronavirus vaccination campaign with technology to help smooth the inoculation process.

Luminare, which launched with the mission of combating sepsis, switched gears after the onset of the coronavirus pandemic to help combat the virus' spread. One of the ways it's doing that is with Innoculate (a mash-up of "innovate" and "inoculate"). The new platform enables organizations like public health departments, fire departments, school systems, and businesses to manage high-volume vaccination initiatives.

Among other benefits, Innoculate automates vaccination sign-ups and scheduling, tracks the number of vaccine batches available, flags previous allergic reactions among vaccine recipients, and helps achieve compliance with federal, state and local health care requirements.

"Usually when you hear news of a new batch of vaccines headed your way, there is dread at the management and distribution overhead. Not anymore," Dr. Sarma Velamuri, CEO of Luminare, says in a release. "Innoculate will help streamline the vaccination process in the fight against COVID-19 and allow for hundreds of thousands of people to get vaccines easily."

One of the first customers of Innoculate is the Corpus Christi-Nueces County Public Health District. Innoculate helped the district vaccinate 9,000 people during the first week of its vaccination effort. Peter Collins, chief information officer of the City of Corpus Christi, says Innoculate allows more vaccinations to be done without adding administrative burdens.

Corpus Christi-Nueces County Public Health District was the first government outfit to use Innoculate. The district also uses Luminare's Quickscreen COVID-19 screening and testing tool.

Dallas County Health and Human Services also is adopting Innoculate. On January 27, Dallas County approved a 12-month contract with Luminare worth up to $601,500.

Other new customers that are lined up for Innoculate include the Abilene-Taylor County Public Health District, Wichita Falls-Wichita County Public Health District, and Brenham-based Blinn College District. Innoculate deals are being finalized with 13 other city and county governments.

Luminare says it wants to "help as many cities and counties in the U.S. that we can." The company asks organizations seeking help with coronavirus vaccination campaigns to email mike.gilbert@luminaremed.com or info@luminaremed.com.

Luminare was founded in 2014 with the goal of preventing sepsis, a life-threatening reaction to a host of infections that triggers about one-third of U.S. hospital deaths. Its sepsis-targeted software is called Sagitta.

After the coronavirus began spreading, Luminare tweaked its sepsis-detection platform, called Quickscreen, to produce a free online self-assessment for people who suspect they've been infected with the virus. The startup was honored for this work as COVID Phoenix in Houston Exponential's inaugural awards program, The Listies. Now, it has added Innoculate to its pandemic-fighting arsenal.

Luminare, based at Texas Medical Center's innovation campus, is a 2018 graduate of the TMCx accelerator. According to Crunchbase, the company has collected more than $1.6 million in funding.

Here's who won big for Houston innovation. Photos courtesy

Houston Exponential names winners of inaugural innovation awards

And the winner is...

In a virtual awards program, Houston Exponential has revealed the winners of the inaugural Listies awards.

The Listies, brought to you by Houston Exponential in partnership with InnovationMap, named the winning companies and people across 12 awards on November 20 at 3 pm as a part of Impact Hub's annual The Houston Innovation Summit (THIS).

Nominations were open until Friday, November 6, and then a group of judges made up of members of the Houston innovation ecosystem reviewed the submissions to settle on the 38 finalists. Click here to see the finalists.

Here's who took home the big wins.

SDO Superstar: MassChallenge Texas

Photo courtesy of MassChallenge

A startup development organization can be an accelerator program, an incubator, or a coworking space — and organizations falling into all three of these sectors were nominated for this category. MassChallenge Texas, which has been running its non-equity, general accelerator program in Houston for two years, stood out to judges to take the win for the SDO Superstar category.

Individual Contributor: Slawek Omylski of SecurityGate

Photo via LinkedIn

The individual contributor award was meant to find and recognize a non-founder who was essential to the success of a Houston startup, and that's exactly how SecurityGate's team sees Slawek Omylski, director of engineering. Not only has he been essential from the start over three years ago when he joined as employee No. 4, but Omylski, when unexpectedly having to move back home to Italy, never missed a single meeting or tech deployment despite being an ocean away from the rest of his team. Known as "Suave" by his teammates, his nominators say Omylski is usually the first to arrive at the office and the last to leave.

Civic Innovation: Annapurna Solutions

Image viaannapurnasolutions.org

Everyone knows that the key to sustainability is reducing, reusing, and recycling, but the fact of the matter is no one has quite perfected recycling. Houston-based Annapurna Solutions is stepping in to help. The company provides innovative technology solutions to address waste and recycling challenges, helping to make cities smart and sustainable — like the company's ReciklApp.

Welcome to Houston: Greentown Labs

Photo via greentownlabs.com

Greentown Labs is a startup development organization, but it's are also a startup itself, but when it opens its doors in Houston in the spring, the organization isn't starting from scratch. After years of working with over 200 climatech companies in the Boston area, Greentown's expansion into Houston means incubating Houston energy tech companies and furthering the conversation and activation within the energy transition.

Investor of the Year: Integr8d Capital

Photo via TMC.edu

John "J.R." Reale has been a well respected mentor, entrepreneur, and investor in Houston for years. His firm Integr8d Capital has invested in several Houston companies, including Liongard from seed stage to series A and series B. Reale is also the entrepreneur in residence for the TMC Innovation Institute.

Corporate Innovator: Houston Methodist

Courtesy of Methodist Hospital/Facebook

Houston Methodist and its Center for Innovation led by Roberta Schwartz is leading health tech innovation in Houston. In January, the hospital opened its Technology Hub, 3,500-square-foot space renovated from a former 18-room patient wing to showcase and test new digital health technologies like virtual reality, ambient listening, wearables, and more. Additionally, the hub helped with the training of dozens of doctors with the rise of telemedicine during COVID-19.

Outstanding Leadership: Grace Rodriguez

Photo courtesy of Grace Rodriguez

Grace Rodriguez's career spans industry and time, but her leadership has been consistent throughout. She currently serves Impact Hub Houston as CEO and executive director. Her nominator calls her an inspiration and someone who "shows up," clearly loving everything she does and is responsible. During COVID-19, she's gone above and beyond to provide resources and information to everyone who needs it, including launching a fund to help pay for meals for health care workers and first responders. The LIFE Fund raised over $20,000.

COVID Phoenix: Luminare

Image via luminaremed.com

Originally founded by Dr. Sarma Velamuri to treat and fight sepsis, Luminare took its sepsis platform and pivoted it to created a COVID self-assessment and testing tool. Their digital platform directed 5.5 million people to COVID-19 testing sites in just 21 days, according to its nomination. The tool was used by Harris County and several other entities.

DEI Champion: Maria Maso

Photo courtesy of Nijalon Dunn

Maria Maso is looking out for minorities when it comes to investment. As the founder and CEO of the Business Angel Minority Association (baMa) — an Angel Association aimed at bridging minority-founded startups with accesses to capital — Maria has been a champion for diversity. She also has helped to educate and activate 40 diverse investors through baMa's Diversity Investor Academy, according to her nomination.

Mentor of the Year: Landi Spearman

Photo via LinkedIn

Landi Spearman's approach to mentorship, according to her nominee, is to mentor the full person — from professional to personal life — through Organized SHIFT, which focuses on helping highly productive leaders, individuals and organizations in their quest to sustain positive growth internally and externally. She also supports entrepreneurs though The Ion, Station Houston, General Assembly, the National Urban League, Power to Fly, Black Women in Science and Engineering, the Greater Houston Partnership, the Greater Houston Black Chamber, Pink Petro, and more.

People's Choice and Soonicorn: Liongard

Photos via LinkedIn

People's Choice was based off how many nominations the startups received, and Liongard was a clear winner. The company, which also won in the Soonicorn category, has experienced major growth and, as the nominations read, that's to both Joe Alapat and Vincent Tran, co-founders, credit. The company has raised $12 million to date — the most recent round, a $10 million Series A — closed this year.

Houston Exponential has announced the 38 finalists for the inaugural Listies Awards. Photo via Getty Images

Exclusive: HX names finalists for inaugural Houston innovation awards

the listies go to...

Ever wonder what Houston startups and innovators are the best of the best? Here's your chance to figure it out. The inaugural Listies awards program has named its finalists.

The Listies, brought to you by Houston Exponential in partnership with InnovationMap, will name the winning companies and people across 12 awards on November 20 at 3 pm at a virtual event as a part of Impact Hub's annual The Houston Innovation Summit (THIS). Click here to register for the free event.

Nominations were open until Friday, November 6, and then a group of judges made up of members of the Houston innovation ecosystem reviewed the submissions to settle on the finalists. Below, in alphabetical order, the 38 finalists are listed for each category.

DEI champion

  • Heath Butler
  • Maria Maso
  • Grace Rodriguez

Individual contributor

  • Michael Matthews
  • Slawek Omylski
  • Brad True

Mentor of the year

  • Keith Kreuer
  • Wade Pinder
  • Landi Spearman

Outstanding leadership

  • Stephanie Campbell
  • Grace Rodriguez
  • Roberta Schwartz

Corporate innovation

  • Chevron Technology Ventures
  • Houston Methodist
  • Shell Ventures

Investor of the year

  • CSL Capital Management
  • Golden Section VC (GSTVC)
  • Integr8d Capital

SDO superstar

  • MassChallenge Houston
  • Rice Alliance
  • TMCx

Welcome to Houston

  • Greentown Labs
  • TestCard
  • Win-Win

Civic engagement

  • Annapurna
  • Luminare
  • McMac Cx

COVID pivot/phoenix

  • Luminare
  • re:3D
  • sEATz

People choice

  • INK
  • Liongard
  • Luminare
  • re:3D
  • Topl

Soonicorn

  • GoExpedi
  • Liongard
  • Medical Informatics Corp.
These Houston startups have created health care-related solutions amid the coronavirus outbreak. Getty Images

These 7 Houston health tech companies are providing COVID-19 solutions

startups to the rescue

It's all hands on deck in Houston in the battle against coronavirus — and local biotech startups have risen to the occasion.

From mental health solutions and online portals to virtual medicine and new treatments, these Houston companies have recently launched or pivoted to new options in health care.

Mental Health Match

Ryan Schwartz is offering free counseling to Texans. Photo courtesy of Mental Health Match

Mental Health Match, a Houston-based startup that uses tech to easily connect people to mental health professionals, has announced the opportunity for 100 Texas residents to get their first appointment free and remotely.

The company cites data that shows:

  • A 78 percent increase in Texans who are concerned about their marriage
  • A 71 percent increase in Texans concerned with their parenting or their children
  • A 35 percent spike in Texans feeling panicked

"You might be practicing social distancing, but you are not alone. It is easier to make it through this together if you can get support and guidance from a skilled professional. That's why we're working with therapists across Texas to provide a free session to individuals who need it most," says Ryan Schwartz, founder of Mental Health Match, in a news release.

Texans can apply for the free sessions online on a first-come, first-served basis.

Medical Informatics Corp.

Medical Informatics Corp.'s Sickbay platform can monitor patients from afar. Photo via michealthcare.com

Houston-based Medical Informatics has created a virtual ICU program, called Sickbay, and the tech tool is being used to remotely monitor patients in Houston Methodist. The program works around the clock from a control hub to use artificial intelligence and algorithms to monitor patients.

The company, which recently moved into its office in TMCx+, announced major growth in January, just ahead of the coronavirus outbreak.

"We designed our Sickbay platform to give lost data back to doctors, nurses and other members of the care team so they could save more lives," says Vincent Gagne, vice president of product for MIC, in a news release. "In fact, our apps are built in collaboration with our clients, such as Texas Children's Hospital and Houston Methodist. Having these facilities blocks away from our headquarters accelerates that collaboration and development."

MolecularMatch

MolecularMatch is bringing together COVID-19 information and trials. Photo via molecularmatch.com

MolecularMatch, a Houston startup focused on clinical informatics, has launched a free portal that accumulates research and clinical trials for COVID-19. The company is a tenant of TMCx+ and a portfolio company of Houston-based venture capital group GOOSE.

"The number of therapeutic cures and vaccines being tested are growing at an astounding rate," says Eric Pulaski, CEO at MolecularMatch, in a news release. "Our tools make it easier for clinicians and patients to find the help they need. Hopefully, we can help save lives by shortening the time it takes to get more patients into clinical trials and by speeding up research to find cures and vaccines."

The product uses the company's artificial intelligence-backed curation platform and is updated every two to three days.

Luminare

Luminare Inc. pivoted to quickly create an online COVID-19 screening tool, and local governments have tapped into the resource. Andriy Onufriyenko/Getty Images

Founded in 2014, Houston-based health care software startup Luminare Inc. seeks to prevent sepsis, a life-threatening reaction to a host of infections that causes about one-third of U.S. hospital deaths. Recently, though, Luminare pivoted to address another health concern — the threat of the novel coronavirus.

After the novel coronavirus surfaced, Luminare retooled its sepsis-detection platform to create a free online self-assessment test for people who suspect they've contracted the virus. The test, available at CheckForCorona.com, helps someone figure out whether they should seek a coronavirus test.

An online screening typically takes less than two minutes. The confidential, secure assessment complies with guidelines from the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). Based on your assessment results, you might be directed to contact your local health department or, in the worst-case scenario, call 911. Click here to read more.

Manatee

Manatee users can sign up for three months free. Photo via getmanatee.com

Denver-based Manatee was just announced to be selected for the 2020 TMCx cohort, and — while programming is beginning virtually — the startup will be enroute to Houston as soon as it's safe. Manatee focuses on providing connected, everyday therapy for kids.

In light of the effects of COVID-19 on both parents and children, Manatee has allowed users to register for three months free. Individuals can apply online.

Moleculin Biotech Inc.

Houston-based Moleculin, which works on oncology treatment, has filed a patent for its treatment to battle the coronavirus. Getty Images

Houston-based Moleculin Biotech Inc., a clinical stage pharmaceutical company that typically focuses on cancer treatment, announced that it has filed for a new patent for its use of one of its products to be used against the coronavirus and other potential viruses.

This patent application is for Moleculin's WP1122, and the company has entered into a partnership with a major Texas university to advance its research.

"We've actually been working on the antiviral potential of WP1122 for some time now," says Walter Klemp, Moleculin's chairman and CEO, in a news release, "but the rise of COVID-19 has obviously placed a new sense of urgency on what we are doing. We hope to be generating animal data on WP1122's antiviral potential in the near term."

Pulmotech Inc.

Pulmotect, a clinical-stage biotechnology company based in Houston, is testing a drug that could be useful in mitigating the threats of the coronavirus, which is currently been recognized as a global health emergency. Getty Images

Experiments conducted by clinical-stage, Houston-based biotechnology company Pulmotect Inc. show its PUL-042 inhaled drug has proven effective in protecting mice against two types of coronavirus: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Researchers performed those tests at the University of Texas Medical Branch at Galveston.

In the Galveston experiments, a single inhaled dose of PUL-042 protected lab mice from the SARS virus, and it greatly reduced the amount of virus in their lungs after the mice became infected with SARS or MERS.

"With the risks of virulent coronaviruses and other threats increasing, as shown by the recent outbreak in Wuhan that has already spread from China to other countries including the United States, Pulmotect is optimistic that its immune-stimulating technology could be useful in mitigating the threats of current and emerging pathogens and protecting vulnerable populations," says CEO Dr. Colin Broom in a news release. Click here to read more.

Luminare Inc. pivoted to quickly create an online COVID-19 screening tool, and local governments have tapped into the resource. Andriy Onufriyenko/Getty Images

Houston health tech startup providing local governments a coronavirus screening tool

contracting COVID-19

Founded in 2014, Houston-based health care software startup Luminare Inc. seeks to prevent sepsis, a life-threatening reaction to a host of infections that causes about one-third of U.S. hospital deaths. Recently, though, Luminare pivoted to address another health concern — the threat of the novel coronavirus.

After the novel coronavirus surfaced, Luminare retooled its sepsis-detection platform to create a free online self-assessment test for people who suspect they've contracted the virus. The test, available at CheckForCorona.com, helps someone figure out whether they should seek a coronavirus test.

An online screening typically takes less than two minutes. The confidential, secure assessment complies with guidelines from the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). Based on your assessment results, you might be directed to contact your local health department or, in the worst-case scenario, call 911.

If you take the self-assessment, you'll be quizzed about:

  • Your age.
  • Whether you've had close in-person contact with somebody who's been diagnosed with COVID-19 disease.
  • Whether you've traveled internationally within the past 14 days.
  • Whether you're feeling sick and what symptoms you're experiencing.
  • Whether you live in a nursing home or similar facility.
  • Whether you're a first responder or health care worker.

During an assessment, you can opt to provide your location or not.

Dr. Sarma Velamuri, an internal medicine physician who is co-founder and CEO of Luminare, says he hopes QuickScreen can eventually enable prediction of coronavirus outbreaks based on symptoms such as a fever. QuickScreen enables communities and organizations to collect anonymous data that can help shed light on the transmission and severity of the coronavirus in certain locations.

As of early April, the free assessment, translated into eight languages, had screened close to 100,000 patients around the world.

Luminare teamed up with the Microsoft for Startups program and Harris County Public Health, as well as Durham, North Carolina-based software developer Cognitect Inc., to develop QuickScreen. Velamuri says QuickScreen is available at no cost to communities, government agencies, and health care organizations to help combat the novel coronavirus. QuickScreen aims to decrease ER overcrowding and reduce health care workers' potential exposure to the virus.

QuickScreen "is available to pretty much anyone who wants it," Velamuri says.

Aside from Harris County Public Health, the QuickScreen platform has been adopted by the city of Houston and Fort Bend County. Luminare created a web-based tool for Houston's Healthcare for the Homeless to determine whether homeless people need testing, require quarantining, or need other health care.

A general public version of QuickScreen is available for anyone it use; geographically tailored versions also are offered. The version adopted by Harris County Public Health encompasses 30 counties in and around the Houston metro area, and can point someone to local health care resources.

Velamuri says it took about 20 days to build the coronavirus tool, while Luminare has spent five years developing the sepsis platform. To help cover the cost of QuickScreen, Luminare is seeking donations, given that it's a small company with just 12 employees.

Luminare has temporarily shifted much of its focus toward QuickScreen and away from sepsis-detection platform, which five hospitals currently use. However, that hardly means the startup has given up tackling a deadly problem that represents an estimated 13 percent of all U.S. hospital costs.

Luminare, which is based at the Texas Medical Center Innovation Institute and is a graduate of the TMCx accelerator, has raised money through angel investments and friends-and-family funding, Velamuri says. Among its investors is Houston-based VC firm Carnrite Ventures. According to Crunchbase, Luminare's seed round totaled $497,500.

"Our core mission is to stop sepsis that's in hospitals," Velamuri says. "That's why we started the company. That's what we're about."

"The future to us looks very much like continuing to stop people from dying of sepsis," he adds, "and building whatever this pandemic takes to fix from a software perspective. We're just going to keep pushing on that."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston hospital joins the metaverse with new platform

now online

Houston Methodist has launched a platform that is taking medical and scientific experts and students into the metaverse.

The MITIEverse, a new app focused on health care education and training, provides hands-on practice, remote assistance from experienced clinicians, and more. The app — named for the Houston Methodist Institute for Technology, Innovation and Education, aka MITIE — was created in partnership with FundamentalVR and takes users into virtual showcase rooms, surgical simulations, and lectures from Houston Methodist faculty, as well as collaborators from across the world.

“This new app brings the hands-on education and training MITIE is known for to a new virtual audience. It could be a first step toward building out a medical metaverse,” says Stuart Corr, inventor of the MITIEverse and director of innovation systems engineering at Houston Methodist, in a news release.

Image courtesy of Houston Methodist

The hospital system's DeBakey Heart and Vascular Center has created a virtual showcase room on the app, and users can view Houston Methodist faculty performing real surgeries and then interact with 3D human models.

"We view the MITIEverse as a paradigm-shifting platform that will offer new experiences in how we educate, train, and interact with the health community,” says Alan Lumsden, M.D., medical director of Houston Methodist DeBakey Heart and Vascular Center, in the release.

“It essentially democratizes access to health care educators and innovators by breaking down physical barriers. There’s no need to travel thousands of miles to attend a conference when you can patch into the MITIEverse," he continues.

Image courtesy of Houston Methodist

Houston doctors get approval for low-cost COVID vaccine abroad

green light

A Houston-born COVID-19 vaccine has gotten the go-ahead to be produced and distributed in Indonesia.

PT Bio Farma, which oversees government-owned pharmaceutical manufacturers in Indonesia, says it’s prepared to make 20 million doses of the IndoVac COVID-19 vaccine this year and 100 million doses a year by 2024. This comes after the vaccine received authorization from the Indonesian Food and Drug Authority for emergency use in adults.

With more than 275 million residents, Indonesia is the world’s fourth most populous country.

IndoVac was created by the Texas Children’s Hospital Center for Vaccine Development and Baylor College of Medicine. Drs. Peter Hotez and Maria Elena Bottazzi lead the vaccine project. Bio Farma is licensing IndoVac from BCM Ventures, the commercial group at the Baylor College of Medicine.

“Access to vaccines in the developing world is critical to the eradication of this virus,” Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, says in a news release.

Aside from distributing the vaccine in Indonesia, Bio Farma plans to introduce it to various international markets.

“The need for a safe, effective, low-cost vaccine for middle- to low-income countries is central to the world’s fight against the COVID-19 pandemic,” says Bottazzi, co-director of the Texas Children’s Hospital Center for Vaccine Development and associate dean of the National School of Tropical Medicine at Baylor.

“Without widespread inoculation of populations in the developing world, which must include safe, effective booster doses, additional [COVID-19] variants will develop, hindering the progress achieved by currently available vaccines in the United States and other Western countries.”

Bio Farma says it has completed Phase 1 and Phase 2 clinical trials for IndoVac and is wrapping up a Phase 3 trial.

IndoVac is a version of the patent-free, low-cost Corbevax vaccine, developed in Houston and dubbed “The World’s COVID-19 Vaccine.” The vaccine formula can be licensed by a vaccine producer in any low- or middle-income country, which then can take ownership of it, produce it, name it, and work with government officials to distribute it, Hotez told The Texas Tribune in February.

Among donors that have pitched in money for development of the vaccine are the Houston-based MD Anderson and John S. Dunn foundations, the San Antonio-based Kleberg Foundation, and Austin-based Tito’s Vodka.

“During 2022, we hope to partner with the World Health Organization and other United Nations agencies to vaccinate the world. We believe that global vaccine equity is finally at hand and that it is the only thing that can bring the COVID pandemic to an end,” Hotez and Bottazzi wrote in a December 2021 article for Scientific American.

Houston research: How best to deliver unexpected news as a company

houston voices

According to Forbes, the volume of mergers and acquisitions in 2021 was the highest on record, and 2022 has already seen a number of major consolidation attempts. Microsoft’s acquisition of video game company Activision Blizzard was the biggest gaming industry deal in history, according to Reuters. JetBlue recently won the bid over Frontier Airlines to merge with Spirit Airlines. And, perhaps most notably, Elon Musk recently backed out of an attempt to acquire Twitter.

It can be hard to predict how markets will react to such high-profile deals (and, in Elon Musk and Twitter’s case, whether or not the deal will even pan out). But Rice Business Professor Haiyang Li and Professor Emeritus Robert Hoskisson, along with Jing Jin of the University of International Business and Economics in Beijing, have found that companies can take advantage of these deals to buffer the effects of other news.

The researchers looked at 7,575 mergers and acquisitions from 2001 to 2015, with a roughly half-and-half split between positive and negative stock market reactions. They found that when there’s a negative reaction to a deal, companies have two strategies for dealing with it. If it’s a small negative reaction, companies will release positive news announcements in an attempt to soften the blow. But when the reaction is really bad, companies actually tend to announce more negative news afterward. Specifically, companies released 18% less positive news and 52% more negative news after a bad market reaction.

This may seem counterintuitive, but there’s a method to the madness, and it all has to do with managing expectations. If people are lukewarm on a company due to a merger or acquisition, it’s possible to sway public opinion with unrelated good news. When the backlash is severe, though, a little bit of good PR won’t be enough to change people’s minds. In this case, companies release more bad news because it’s one of their best chances to do so without making waves in the future. If people already think poorly of a company due to a recent deal, more bad news isn’t great, but it doesn’t come as a surprise, either. Therefore, it’s easier to ignore.

It might make more sense to just keep quiet if the market reaction to a deal is bad, and this study found that most companies do. However, this only applies when releasing more news would make a mildly bad situation worse. If things are already bad enough that the company can’t recover with good news, it can still make the best out of a bad situation by offloading more bad news when the damage will be minimal. Companies are legally obligated to disclose business-related news or information with shareholders and with the public. If it’s bad news, they like to share it when the public is already upset about a deal, instead of releasing the negative news when there are no other distractions. In this case the additional negative news is likely to get more play in the media when disclosed by itself.

But what happens when people get excited about a merger or acquisition? In these cases, it also depends on how strong the sentiment is. If the public’s reaction is only minimally positive, companies may opt to release more good news in hopes of making the reaction stronger. When the market is already enthusiastic about the deal, though, companies won’t release more positive news. The researchers found that after an especially positive market reaction to a deal, companies indeed released 12% less positive news but 56% more negative news. Also, one could argue that the contrasting negative news makes the good news on the acquisition look even better. This may be important especially if the acquisition is a significant strategic move.

There are several reasons why a company wouldn’t continue to release positive news after a good press day and strong market reaction. First of all, they want to make sure that a rise in market price is attributed to the deal alone, and not any irrelevant news. A positive reaction to a deal also gives companies another opportunity to disclose bad news at a time when it will get less attention. If the bad news does get attention, the chances are better that stakeholders will go easy on them — a little bit of bad press is forgivable when the good news outshines it.

Companies may choose to release no news after a positive reaction to a merger or acquisition, the same way they might opt to stay quiet after backlash. They’re less likely to release positive news when stakeholders are already happy, preferring to save that news for the next time they need it, either to offset a negative reaction or strengthen a weak positive reaction.

Mergers and acquisitions can produce unpredictable market reactions, so it’s important for companies to be prepared for a variety of outcomes. In fact, Jin, Li and Hoskisson found that the steps taken by companies before deals were announced didn’t have much effect on the public’s reaction. They found that it’s more important for companies to make the best out of that reaction, whatever it turns out to be.

The researchers also found that, regardless of whether the market reaction was positive or negative, as long as the reaction was strong, companies could use the opportunity to hide smaller pieces of bad news in the shadow of a headline-making deal. Overall, the magnitude of the reaction mattered more than the type of reaction. People tend to have stronger reactions to unexpected news, though, so companies prefer to release negative news when market expectations are already low.

These findings are relevant beyond merger announcements, of course; they also point to strategies that could be useful in everyday communications. A key takeaway is that negative information is less upsetting when people already expect bad things — or when it comes after much bigger, and much better, news. Bad news is always hard to deliver, but this research gives us a few ways to soften the blow.

------

This article originally ran on Rice Business Wisdom and was based on research from Jing Jin, Haiyang Li and Robert Hoskisson.